
Medline Inc (MDLN) Stock Forecast & Price Target
Medline Inc (MDLN) Analyst Ratings
Bulls say
Medline experienced a significant increase in sales revenue, rising 11.47% year-over-year from $25.51 billion to $28.43 billion for the 12 months ending December 2025. The company's Return on Capital improved from 7.22% to 7.44%, indicating enhanced financial efficiency and profitability, while it also secured $2.4 billion in new customer signings, demonstrating robust demand for its Medline-branded products and supply chain solutions. With the Medline Brand now contributing to nearly half of the company's revenue and strong growth prospects forecasted to reach $31.12 billion, Medline is well-positioned to capitalize on its extensive manufacturing capabilities and established vendor relationships in the healthcare sector.
Bears say
Medline's economic profit showcased a stark decline of 220.79% year-over-year, shifting from a profit of $345.1 million pre-IPO to a significant loss of $416.9 million post-IPO, reflecting negative trends in equity cost measurements. Additionally, Net Operating Profit After Tax (NOPAT) fell by 12.66% year-over-year, decreasing from $2.45 billion to $2.14 billion, along with a 4.48% decline in Economic Operating Cash Flow (EBITDAR) from $3.71 billion to $3.54 billion, highlighting ongoing profitability challenges. The company faces pressure from elevated inflation, hiring challenges, low-margin healthcare operations, competitive market dynamics, and reliance on sustaining Prime Vendor agreements, all of which could adversely affect revenue growth and operational stability.
This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.
Medline Inc (MDLN) Analyst Forecast & Price Prediction
Start investing in Medline Inc (MDLN)
Order type
Buy in
Order amount
Est. shares
0 shares